Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETINO 2018: Conservative Treatment for Retinoblastoma
2024-514025-30-00Phase 2Authorised
- Sponsor
- Institut Curie
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of topotecan, melphalan, vincristine, etoposide and carboplatin in retinoblastoma (Rb) (3 arms), sponsored by Institut Curie. Primary endpoints: Eye preservation rate at 24 months (Study 1) and Visual function at 6 years (Study 2). Planned start May 2024; status: authorised.
02
Drugs
topotecanmelphalanvincristineetoposidecarboplatin
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on 2024-514025-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514025-30-00.